GlassScriptPhysician profile
Lowell R Searight
NPI 1659343671
$3,038.67
in general payments reported to CMS, 2019-2025
32 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $172 · 2021: $343 · 2022: $678 · 2023: $468 · 2024: $691 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $406.10 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $386.33 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $340.94 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $328.18 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.95 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $174.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $150.43 | 2022-2025 | |
| Novo Nordisk INC | $108.14 | 2020-2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.86 | 2021-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $77.24 | 2021-2025 | Austedo Xr, Austedo Xr |
| Genzyme Corporation | $76.99 | 2019-2024 | |
| Lundbeck LLC | $68.47 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $65.07 | 2019-2022 | |
| Roche Diagnostics Corporation | $61.37 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.31 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.91 | 2023 | Freestyle Libre 2 |
| Sanofi Pasteur INC. | $38.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $37.79 | 2023 | Nuedexta |
| Boston Scientific Corporation | $32.36 | 2024 | Watchman Flx |
| Pfizer INC. | $29.11 | 2023 | |
| Viatris Specialty LLC | $27.95 | 2025 | Yupelri |
| Aimmune Therapeutics, INC. | $25.95 | 2025 | Zenpep |
| Mdd US Operations, LLC | $20.66 | 2022 | |
| Dexcom, INC. | $18.32 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $16.98 | 2024 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $15.82 | 2024 | Voquezna |
| Exact Sciences Corporation | $15.53 | 2025 | Cologuard Collection Kit |
| Philips North America LLC | $15.43 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.49 | 2022 | |
| Astellas Pharma US INC | $13.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Searight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.